Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | AKT2 | P31751 | 2/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | PPARD | Q03181 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | CPT1A | P50416 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515253 | 0.86 | AKT1 (0.37) | PTGDR2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL515252 | 0.86 | AKT1 (0.37) | PTGDR2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL513508 | 0.83 | XIAP (0.36) | MEN1ALDH1A1MAPTKMT2AAKT1 | |
| SCHEMBL514755 | 0.82 | AKT1 (0.49) | ALOX5AKT1AKT2 | |
| SCHEMBL10141078 | 0.82 | AKT1 (0.49) | ALOX5AKT1AKT2 | |
| SCHEMBL514754 | 0.82 | AKT1 (0.49) | ALOX5AKT1AKT2 | |
| SCHEMBL514025 | 0.81 | XIAP (0.37) | MEN1ALDH1A1MAPTKMT2AAKT1 | |
| SCHEMBL514026 | 0.81 | XIAP (0.37) | MEN1ALDH1A1MAPTKMT2AAKT1 | |
| SCHEMBL513117 | 0.81 | ALDH1A1 (0.47) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL513116 | 0.81 | ALDH1A1 (0.47) | MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | PTGDR2 3046/4885MEN1 465/4885ALDH1A1 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.